合并症对急性心肌梗死峰值肌钙蛋白水平及死亡率的影响
结果显示,慢性肾病(CKD)患者调整后峰值cTnT显著升高(+42%),而慢性阻塞性肺疾病(COPD)、既往心绞痛、既往心肌梗死和慢性心力衰竭(CHF)患者峰值cTnI显著降低;多数合并症调整峰值cTn后180天死亡风险无实质变化。结论认为合并症显著影响cTn系统浓度,且无论峰值cTn水平如何,合并症均是死亡的重要预测因素。
要点
- CKD患者调整后峰值cTnT较无CKD者高42%(95%CI 13.1-78.4)。
- COPD、既往心绞痛、既往MI和CHF患者峰值cTnI显著低于无相应合并症者。
- 多数合并症调整峰值cTn后180天死亡风险无实质变化,合并症本身是死亡预测因素。
核心结论
- 合并症显著影响AMI患者峰值cTn的系统浓度。
- 合并症是死亡的显著预测因素,且不受峰值cTn水平影响。
- 解读cTn作为诊断和预后生物标志物时应考虑合并症。
研究设计与样本
- 采用线性回归评估八种常见合并症与峰值cTn的关联,并调整年龄、性别、吸烟状态和合并症。
- 采用逻辑回归和限制性立方样条模型分析峰值cTn与180天死亡率的关联。
主要发现
- CKD患者调整后峰值cTnT较无CKD者高42%(95%CI 13.1-78.4)。
- COPD患者调整后峰值cTnI较无COPD者低21.7%(95%CI -29.1至-13.4)。
- 既往心绞痛患者调整后峰值cTnI较无既往心绞痛者低24.2%(95%CI -29.6至-8.3)。
- 既往MI患者调整后峰值cTnI较无既往MI者低13.5%(95%CI -20.6至-5.9)。
- CHF患者调整后峰值cTnI较无CHF者低28%(95%CI -37.2至-17.6)。
临床怎么用
- 解读AMI患者cTn水平时应考虑合并症对cTn浓度的影响。
- 合并症应纳入AMI患者死亡风险评估, regardless of peak cTn levels。
- cTnI与死亡率的关联总体上强于cTnT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterise peak cardiac troponin levels, in patients presenting with acute myocardial infarction (AMI), according to their comorbid condition and determine the influence of peak cardiac troponin (cTn) levels on mortality. METHODS: We included patients with the first admission for AMI in the UK. We used linear regression to estimate the association between eight common comorbidities (diabetes mellitus, previous angina, peripheral arterial disease, previous myocardial infarction (MI), chronic kidney disease (CKD), cerebrovascular disease, chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD)) and peak cTn. Peak cTn levels were adjusted for age, sex, smoking status and comorbidities. Logistic regression and restricted cubic spline models were employed to investigate the association between peak cTn and 180-day mortality for each comorbidity. RESULTS: 330 367 patients with ST elevation myocardial infarction and non-ST elevation myocardial infarction were identified. Adjusted peak cTn levels were significantly higher in patients with CKD (adjusted % difference in peak cTnT for CKD=42%, 95% CI 13.1 to 78.4) and significantly lower for patients with COPD, previous angina, previous MI and CHF when compared with patients without the respective comorbidities (reference group) (cTnI; COPD=-21.7%, 95% CI -29.1 to -13.4; previous angina=-24.2%, 95% CI -29.6 to -8.3; previous MI=-13.5%, 95% CI -20.6 to -5.9; CHF=-28%, 95% CI -37.2 to -17.6). Risk of 180-day mortality in most of the comorbidities did not change substantially after adjusting for peak cTn. In general, cTnI had a stronger association with mortality than cTnT. CONCLUSIONS: In this nationwide analysis of patients presenting with AMI, comorbidities substantially influenced systemic concentrations of peak cTn. Comorbid illness is a significant predictor of mortality regardless of peak cTn levels and should be taken into consideration while interpreting cTn both as a diagnostic and prognostic biomarker.
引用
- Sundaram V, Rothnie K, Bloom C, et al. Impact of comorbidities on peak troponin levels and mortality in acute myocardial infarction. Heart. 2020. PMID: 32102896. doi:10.1136/heartjnl-2019-315844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。